This association was further substantiated through co-immunostaining experiments, affirming a heightened co-expression of BMI1 and CD44/CD133/SOX9 in HCC patients exhibiting high BMI1 expression, in contrast to those with low BMI1 expression (Supplementary Fig. 1c). Here, SOX9 is linked to hepatocellular carcinoma.